Samarth Kulkarni - Mar 10, 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: Chief Executive Officer, Director
Signature: /s/ Michael Esposito, attorney-in-fact
Stock symbol: CRSP
Transactions as of: Mar 10, 2022
Transactions value $: -$596,932
Form type: 4
Date filed: 3/14/2022, 06:12 PM
Previous filing: Feb 22, 2022
Next filing: May 16, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRSP	Common Shares	Options Exercise		+11.8K	+4.24%		291K	Mar 10, 2022	Direct	F1
transaction	CRSP	Common Shares	Tax liability	-$343K	-5.49K	-1.89%	$62.56	285K	Mar 11, 2022	Direct	F2
transaction	CRSP	Common Shares	Options Exercise		+9K	+3.15%		294K	Mar 11, 2022	Direct	F1
transaction	CRSP	Common Shares	Tax liability	-$254K	-4.15K	-1.41%	$61.08	290K	Mar 14, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRSP	Restricted Stock Units	Options Exercise		-11.8K	-50%		11.8K	Mar 10, 2022	Common Shares	11.8K		Direct	F1, F3
transaction	CRSP	Restricted Stock Units	Options Exercise		-9K	-25%		27K	Mar 11, 2022	Common Shares	9K		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2	Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3	This restricted stock unit award was granted on March 10, 2020 with respect to 35,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.
F4	This restricted stock unit award was granted on March 11, 2021 with respect to 36,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024 and (iv) one quarter of the shares vesting on March 11, 2025.